StockNews.com Upgrades XOMA (NASDAQ:XOMA) to “Hold”

XOMA (NASDAQ:XOMA) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Separately, HC Wainwright reissued a “buy” rating and issued a $104.00 target price on shares of XOMA in a report on Wednesday.

XOMA Stock Performance

Shares of NASDAQ XOMA opened at $20.88 on Friday. XOMA has a one year low of $19.92 and a one year high of $35.00. The firm has a market cap of $250.12 million, a price-to-earnings ratio of -6.00 and a beta of 1.00. The stock’s fifty day moving average price is $24.37 and its two-hundred day moving average price is $27.13. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The company had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. On average, equities analysts forecast that XOMA will post -1.41 EPS for the current year.

Insider Transactions at XOMA

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. 7.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in XOMA. BNP Paribas Financial Markets grew its stake in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the period. State Street Corp boosted its holdings in shares of XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after buying an additional 1,754 shares in the last quarter. Barclays PLC grew its position in shares of XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares during the period. Geode Capital Management LLC increased its stake in shares of XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after acquiring an additional 1,138 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of XOMA by 18.1% during the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 1,699 shares during the period. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.